MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 565233 | Name: Sulindac Sulfide
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Sulindac Sulfide is a metabolite of sulindac.

Chemical Structure

Sulindac Sulfide
Sulindac Sulfide
CAS#49627-27-2; 32004-67-4

Theoretical Analysis

MedKoo Cat#: 565233

Name: Sulindac Sulfide

CAS#: 49627-27-2; 32004-67-4

Chemical Formula: C20H17FO2S

Exact Mass: 340.0933

Molecular Weight: 340.41

Elemental Analysis: C, 70.57; H, 5.03; F, 5.58; O, 9.40; S, 9.42

Price and Availability

Size Price Availability Quantity
5mg USD 350.00
10mg USD 500.00
25mg USD 700.00
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Sulindac Sulfide
IUPAC/Chemical Name
2-[(3Z)-6-Fluoro-2-methyl-3-[(4-methylsulfanylphenyl)methylidene]inden-1-yl]acetic acid
InChi Key
LFWHFZJPXXOYNR-MFOYZWKCSA-N
InChi Code
InChI=1S/C20H17FO2S/c1-12-17(9-13-3-6-15(24-2)7-4-13)16-8-5-14(21)10-19(16)18(12)11-20(22)23/h3-10H,11H2,1-2H3,(H,22,23)/b17-9-
SMILES Code
O=C(O)CC1=C(C)/C(C2=C1C=C(F)C=C2)=C/C3=CC=C(SC)C=C3
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 340.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Thi Thanh Nguyen N, Yoon Lee S. Celecoxib and sulindac sulfide elicit anticancer effects on PIK3CA-mutated head and neck cancer cells through endoplasmic reticulum stress, reactive oxygen species, and mitochondrial dysfunction. Biochem Pharmacol. 2024 Jun;224:116221. doi: 10.1016/j.bcp.2024.116221. Epub 2024 Apr 18. PMID: 38641308. 2: Hossain F, Ucar DA, Monticone G, Ran Y, Majumder S, Larter K, Luu H, Wyczechowska D, Heidari S, Xu K, Shanthalingam S, Matossian M, Xi Y, Burow M, Collins-Burow B, Del Valle L, Hicks C, Zabaleta J, Golde T, Osborne B, Miele L. Sulindac sulfide as a non-immune suppressive γ-secretase modulator to target triple-negative breast cancer. Front Immunol. 2023 Oct 13;14:1244159. doi: 10.3389/fimmu.2023.1244159. PMID: 37901240; PMCID: PMC10612326. 3: Itoh H, Yamashita N, Kamijo S, Masuda K, Kato H, Yamaori S. Effects of acidic non-steroidal anti-inflammatory drugs on human cytochrome P450 4A11 activity: Roles of carboxylic acid and a sulfur atom in potent inhibition by sulindac sulfide. Chem Biol Interact. 2023 Sep 1;382:110644. doi: 10.1016/j.cbi.2023.110644. Epub 2023 Jul 25. PMID: 37499995. 4: Hong Y, Kim I, Moon H, Lee J, Lertpatipanpong P, Ryu CH, Jung YS, Seok J, Kim Y, Ryu J, Baek SJ. Novel thrombospondin-1 transcript exhibits distinctive expression and activity in thyroid tumorigenesis. Oncogene. 2023 Jun;42(22):1832-1842. doi: 10.1038/s41388-023-02692-9. Epub 2023 Apr 13. PMID: 37055552. 5: Yuan Y, Liu J, Duan H, Zhang C, Wu W, Qin Q, Lou J, Zhang Q, Wang Q, Li X, Zhou X. An anticoagulant/procoagulant self-converting and bleeding site- targeting systemic nanotherapy for rapidly controlling noncompressible bleeding without risk of thrombosis. J Thromb Haemost. 2023 Jun;21(6):1478-1492. doi: 10.1016/j.jtha.2023.02.020. Epub 2023 Mar 4. PMID: 36871669. 6: Tinsley HN, Mathew B, Chen X, Maxuitenko YY, Li N, Lowe WM, Whitt JD, Zhang W, Gary BD, Keeton AB, Grizzle WE, Grubbs CJ, Reynolds RC, Piazza GA. Novel Non- Cyclooxygenase Inhibitory Derivative of Sulindac Inhibits Breast Cancer Cell Growth In Vitro and Reduces Mammary Tumorigenesis in Rats. Cancers (Basel). 2023 Jan 20;15(3):646. doi: 10.3390/cancers15030646. PMID: 36765604; PMCID: PMC9913705. 7: Kostantini C, Arora S, Söderlind E, Ceulemans J, Reppas C, Vertzoni M. Usefulness of Optimized Human Fecal Material in Simulating the Bacterial Degradation of Sulindac and Sulfinpyrazone in the Lower Intestine. Mol Pharm. 2022 Jul 4;19(7):2542-2548. doi: 10.1021/acs.molpharmaceut.2c00224. Epub 2022 Jun 21. PMID: 35729720. 8: Hirosawa K, Fukami T, Nagaoka M, Nakano M, Nakajima M. Methionine Sulfoxide Reductase A in Human and Mouse Tissues is Responsible for Sulindac Activation, Making a Larger Contribution than the Gut Microbiota. Drug Metab Dispos. 2021 May;50(5):725-733. doi: 10.1124/dmd.122.000828. Epub 2022 Mar 12. PMID: 35279645. 9: Onasanwo SA, Adebimpe-John OE, Olopade FE, Olajide OO. Kolaviron protects rats from cognitive decline induced by Lipopolysaccharide in Wistar rat. Niger J Physiol Sci. 2021 Jun 30;36(1):67-76. PMID: 34987251. 10: Ren Y, Labinsky H, Palmowski A, Bäcker H, Müller M, Kienzle A. Altered molecular pathways and prognostic markers in active systemic juvenile idiopathic arthritis: integrated bioinformatic analysis. Bosn J Basic Med Sci. 2022 Apr 1;22(2):247-260. doi: 10.17305/bjbms.2021.6016. PMID: 34480465; PMCID: PMC8977090. 11: Xu Y, Kong J, Hu P. Computational Drug Repurposing for Alzheimer's Disease Using Risk Genes From GWAS and Single-Cell RNA Sequencing Studies. Front Pharmacol. 2021 Jun 30;12:617537. doi: 10.3389/fphar.2021.617537. PMID: 34276354; PMCID: PMC8277916. 12: Zhao H, Yi B, Liang Z, Phillips C, Lin HY, Riker AI, Xi Y. Cyclin G2, a novel target of sulindac to inhibit cell cycle progression in colorectal cancer. Genes Dis. 2020 Nov 16;8(3):320-330. doi: 10.1016/j.gendis.2020.11.006. PMID: 33997179; PMCID: PMC8093647. 13: Bortolussi S, Catucci G, Gilardi G, Sadeghi SJ. N- and S-oxygenation activity of truncated human flavin-containing monooxygenase 3 and its common polymorphic variants. Arch Biochem Biophys. 2021 Jan 15;697:108663. doi: 10.1016/j.abb.2020.108663. Epub 2020 Nov 2. PMID: 33152328. 14: Cansaran-Duman D, Tanman Ü, Yangın S, Atakol O. The comparison of miRNAs that respond to anti-breast cancer drugs and usnic acid for the treatment of breast cancer. Cytotechnology. 2020 Oct 30;72(6):855–72. doi: 10.1007/s10616-020-00430-7. Epub ahead of print. PMID: 33128199; PMCID: PMC7695759. 15: Lemmens G, Brouwers J, Snoeys J, Augustijns P, Vanuytsel T. Insight into the Colonic Disposition of Sulindac in Humans. J Pharm Sci. 2021 Jan;110(1):259-267. doi: 10.1016/j.xphs.2020.09.034. Epub 2020 Sep 28. PMID: 33002468. 16: Ekanem TI, Tsai WL, Lin YH, Tan WQ, Chang HY, Huang TC, Chen HY, Lee KH. Identification of the Effects of Aspirin and Sulindac Sulfide on the Inhibition of HMGA2-Mediated Oncogenic Capacities in Colorectal Cancer. Molecules. 2020 Aug 22;25(17):3826. doi: 10.3390/molecules25173826. PMID: 32842685; PMCID: PMC7504004. 17: Rayner MLD, Grillo A, Williams GR, Tawfik E, Zhang T, Volitaki C, Craig DQM, Healy J, Phillips JB. Controlled local release of PPARγ agonists from biomaterials to treat peripheral nerve injury. J Neural Eng. 2020 Aug 11;17(4):046030. doi: 10.1088/1741-2552/aba7cc. PMID: 32780719. 18: Tan X, Tang H, Gong L, Xie L, Lei Y, Luo Z, He C, Ma J, Han S. Integrating Genome-Wide Association Studies and Gene Expression Profiles With Chemical-Genes Interaction Networks to Identify Chemicals Associated With Colorectal Cancer. Front Genet. 2020 Apr 24;11:385. doi: 10.3389/fgene.2020.00385. PMID: 32391058; PMCID: PMC7193025. 19: Sung JW, Yun HY, Park S, Kim YJ, Yee J, Lee KE, Song B, Chung JE, Gwak HS. Population Pharmacokinetics of Sulindac and Genetic Polymorphisms of FMO3 and AOX1 in Women with Preterm Labor. Pharm Res. 2020 Jan 28;37(3):44. doi: 10.1007/s11095-020-2765-6. PMID: 31993760. 20: Torabizadeh SA, Rezaeifar M, Jomehzadeh A, Nabizadeh Haghighi F, Ansari M. Radioprotective Potential of Sulindac Sulfide to Prevent DNA Damage Due to Ionizing Radiation. Drug Des Devel Ther. 2019 Dec 6;13:4127-4134. doi: 10.2147/DDDT.S218022. PMID: 31827319; PMCID: PMC6902880.